SentreHEART, Inc.

Founded in 2005, SentreHEART is focused on remote suture delivery for immediate and complete closure of anatomic structures. SentreHEART is committed to clinical evidence development and is currently sponsoring the FDA-approved prospective, multi-center, randomized controlled trial known as the aMAZE Trial. This trial is designed to demonstrate the additive benefits of LARIAT LAA closure combined with pulmonary vein isolation as a means of improving outcomes in patients with persistent or longstanding persistent atrial fibrillation.